<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197701</url>
  </required_header>
  <id_info>
    <org_study_id>143201525127</org_study_id>
    <nct_id>NCT03197701</nct_id>
  </id_info>
  <brief_title>Maximal Effort-dependent Respiratory Flow Rates</brief_title>
  <official_title>Maximal Effort-dependent Respiratory Flow Rates: Reproducibility and Reference Values</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of this project is to determine the best method to measure maximal
      inspiratory flow rates, to study their reproducibility and create reference equations in
      healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Reproducibility and reference values in normal subjects: the investigators will propose
           a method for measurement of the maximal inspiratory flow rates (MIFR) and establish
           their reproducibility in normal subjects. The variability of these inspiratory flow
           rates will be compared with the variability of effort dependent and non-effort dependent
           expiratory flow rates.

           Also, reference equations will be drawn up and compared to the only existing set of
           reference values (2) (needing a revision).

        2. Reproducibility in disease: the investigators will evaluate the reproducibility of the
           MIFR in patients with neuromuscular diseases (Steinert muscular dystrophy, amyotrophic
           lateral sclerosis) and with upper airway obstruction (tracheal stenosis, thyroid
           enlargement) and compare to the reproducibility of expiratory flow rates in this
           population.

        3. Monitoring of diseases: In the neuromuscular patients MIFR will be correlated to the
           existing parameters used for monitoring of these diseases (respiratory muscle strength,
           forced vital capacity), with a longitudinal follow-up.

      In the patients with upper airway obstruction the MIFR (quantitative measurement) will be
      compared to the visual inspection (qualitative interpretation) of the maximal flow-volume
      loop and also the evolution after a therapeutic intervention (airway stenting, thyroidectomy)
      will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Normal values for maximal inspiratory flow rates</measure>
    <time_frame>3 years</time_frame>
    <description>Peak inspiratory flow rate (PIF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normal values for maximal inspiratory flow rates</measure>
    <time_frame>3 years</time_frame>
    <description>Maximal flow rate when 50% of inspiratory vital capacity has been inhaled (FIF50)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of maximal inspiratory flow rates</measure>
    <time_frame>3 years</time_frame>
    <description>Coefficient of variation for peak inspiratory flow rate (PIF)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Function</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Normal healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy hospital workers or visitors

        Exclusion Criteria:

          -  current smokers or ex-smokers with a history of &gt; 80 PY

          -  Presence or history of serious illness or thorax deformity (questionnaire)

          -  recent respiratory tract infection (1 week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane Hanon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shane Hanon, MD</last_name>
    <phone>+3224776841</phone>
    <email>shane.hanon@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Schuermans, RN</last_name>
    <email>daniel.schuermans@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Schuermans, RN</last_name>
    </contact>
    <investigator>
      <last_name>Shane Hanon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung function</keyword>
  <keyword>Inspiratory flow rates</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

